It has been demonstrated that anti-Clec9A nanoemulsion bearing OVA or its CD8 and CD4 epitopes can efficiently induce CTL and T helper responses, as well as inhibit tumor growth in mice bearing PyMT-ChOVA breast cancer cells. This evidence concerns the gene CLEC9A and neoplasm.